They concluded that PAC exhibits anti-colon cancer properties that have potential, by targeting cyclin D1 and suppressing JAK2/STAT3, AKT/mTOR and MEK/ERK signaling pathways as well as their common downstream effector which is cyclin D125. Here, AKT1 is linked to malignant colon neoplasm.